Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Diagnostic and Differential Diagnostic Significance of a Combination of PIVKA-II and Other Tumor Markers in Hepatocellular Carcinoma
Brief Summary: The incidence of Hepatocellular carcinoma (HCC) is increasing worldwide. However, most of HCC cases were at advanced stage when the diagnosis established.Early diagnosis improves the prognosis.The study is intended to evaluate the diagnostic efficiency of Protein Induced by Vitamin K Absence or antagonist-II(PIVKA-II). This study is a international multicenter study joined by several hospitals in China,Singapore,Thailand and Vietnam. Participants including healthy control,HCC,metastatic liver cancer,Hepatitis B virus(HBV) and liver cirrhosis are consecutively recruited into the cohort. All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum samples were tested for PIVKA-II,alpha-fetoprotein and biochemical indexes including alanine aminotransferase(ALT),aspartate aminotransferase(AST),gamma-glutamyl transferase(GGT),alpha-l-fucosidase(AFU),etc.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Peginterferon alfa-2a + Ribavirin, Drug: Peginterferon alfa-2a | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Peginterferon alfa-2a + Ribavirin | Intervention Type: DRUG; Name: Peginterferon alfa-2a + Ribavirin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Peginterferon alfa-2a; Assigned to Arm(s): 1
B: Arm Label: Cohort A, Group 1 (12 wk): CPT Class B (7-9); Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: Cohort A, Group 1 (24 wk): CPT Class B (7-9); Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: Cohort A, Group 2 (12 wk): CPT Class C (10-12); Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: Cohort A, Group 2 (24 wk): CPT Class C (10-12); Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: Cohort B, Group 3 (12 wk): F0-F3 Fibrosis; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: Cohort B, Group 3 (24 wk): F0-F3 Fibrosis; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: Cohort B, Group 4 (12 wk): CPT Class A (5-6); Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: Cohort B, Group 4 (24 wk): CPT Class A (5-6); Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: Cohort B, Group 5 (12 wk): CPT Class B (7-9); Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: Cohort B, Group 5 (24 wk): CPT Class B (7-9); Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: Cohort B, Group 6 (12 wk): CPT Class C (10-12); Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: Cohort B, Group 6 (24 wk): CPT Class C (10-12); Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: Cohort B, Group 7 (12 wk): FCH; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: Cohort B, Group 7 (24 wk): FCH; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Intervention Type: DRUG; Name: LDV/SOF; Assigned to Arm(s): Cohort A, Group 1 (12 wk): CPT Class B (7-9), Cohort A, Group 1 (24 wk): CPT Class B (7-9), Cohort A, Group 2 (12 wk): CPT Class C (10-12), Cohort A, Group 2 (24 wk): CPT Class C (10-12), Cohort B, Group 3 (12 wk): F0-F3 Fibrosis, Cohort B, Group 3 (24 wk): F0-F3 Fibrosis, Cohort B, Group 4 (12 wk): CPT Class A (5-6), Cohort B, Group 4 (24 wk): CPT Class A (5-6), Cohort B, Group 5 (12 wk): CPT Class B (7-9), Cohort B, Group 5 (24 wk): CPT Class B (7-9), Cohort B, Group 6 (12 wk): CPT Class C (10-12), Cohort B, Group 6 (24 wk): CPT Class C (10-12), Cohort B, Group 7 (12 wk): FCH, Cohort B, Group 7 (24 wk): FCH | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): Cohort A, Group 1 (12 wk): CPT Class B (7-9), Cohort A, Group 1 (24 wk): CPT Class B (7-9), Cohort A, Group 2 (12 wk): CPT Class C (10-12), Cohort A, Group 2 (24 wk): CPT Class C (10-12), Cohort B, Group 3 (12 wk): F0-F3 Fibrosis, Cohort B, Group 3 (24 wk): F0-F3 Fibrosis, Cohort B, Group 4 (12 wk): CPT Class A (5-6), Cohort B, Group 4 (24 wk): CPT Class A (5-6), Cohort B, Group 5 (12 wk): CPT Class B (7-9), Cohort B, Group 5 (24 wk): CPT Class B (7-9), Cohort B, Group 6 (12 wk): CPT Class C (10-12), Cohort B, Group 6 (24 wk): CPT Class C (10-12), Cohort B, Group 7 (12 wk): FCH, Cohort B, Group 7 (24 wk): FCH
C: Arm Label: Healthy control; Type: N/A; Interventions: Diagnostic Test: PIVKA-II | Arm Label: Metastatic liver cancer patients; Type: N/A; Interventions: Diagnostic Test: PIVKA-II | Arm Label: Hepatocellular carcinoma patients; Type: N/A; Interventions: Diagnostic Test: PIVKA-II | Arm Label: Chronic liver disease patients; Type: N/A; Interventions: Diagnostic Test: PIVKA-II | Intervention Type: DIAGNOSTIC_TEST; Name: PIVKA-II; Assigned to Arm(s): Chronic liver disease patients, Healthy control, Hepatocellular carcinoma patients, Metastatic liver cancer patients
D: Arm Label: LDV/SOF; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: Placebo to match RBV | Arm Label: LDV/SOF + RBV; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV, Drug: Placebo to match LDV/SOF, Drug: Placebo to match RBV | Intervention Type: DRUG; Name: LDV/SOF; Assigned to Arm(s): LDV/SOF, LDV/SOF + RBV | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): LDV/SOF + RBV | Intervention Type: DRUG; Name: Placebo to match LDV/SOF; Assigned to Arm(s): LDV/SOF + RBV | Intervention Type: DRUG; Name: Placebo to match RBV; Assigned to Arm(s): LDV/SOF, LDV/SOF + RBV

Answer: C